Axsome Therapeutics Inc (STU:19X)
€ 81.28 -1.42 (-1.74%) Market Cap: 3.94 Bil Enterprise Value: 3.83 Bil PE Ratio: 0 PB Ratio: 40.50 GF Score: 36/100

Axsome Therapeutics Inc Investor R&D Call with Migraine Key Opinion Leaders (KOLs) Focusing on AXS-07 Transcript

Nov 25, 2019 / 02:00PM GMT
Release Date Price: €30.4 (+1.33%)
Operator

Good morning, ladies and gentlemen. And welcome to Axsome Therapeutics Conference Call and Webcast. (Operator Instructions) As a reminder, today's conference call is being recorded.

I would now like to turn the conference over to your host, Mark Jacobson, Senior Vice President of Operations at Axsome Therapeutics. Please go ahead.

Mark Jacobson
Axsome Therapeutics, Inc. - SVP of Operations & Secretary

Thank you, operator. Good morning, and thank you all for joining us on today's conference call, focusing on AXS-07 and the unmet needs in the acute treatment of migraine.

During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates, our clinical and nonclinical plans, our plans to present or report additional data, the anticipated conduct and the source of future clinical trials, regulatory plans, future research and development, and possible intended utilization of cash and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot